Ivosidenib Produces Encouraging OS Data in Previously Treated Cholangiocarcinoma
Andrew X. Zhu, MD, PhD, discusses the final results from the phase 3 ClarIDHy study of ivosidenib versus placebo as treatment of patients with previously treated cholangiocarcinoma and an IDH1 mutation.
Andrew X. Zhu, MD, PhD, professor of medicine at the Harvard Medical School and director of Liver Cancer Research at the Massachusetts General Hospital Cancer Center, discusses the final results from the phase 3 ClarIDHy study of ivosidenib (Tibsovo) versus placebo as treatment of patients with previously treated cholangiocarcinoma and an IDH1 mutation.
Overall, the findings demonstrated a numeric improvement in overall survival (OS) with ivosidenib compared with placebo. In the intent-to-treat population, the median OS was 10.3 months with ivosidenib versus 7.5 months with placebo. Interestingly, Zhu says 70% of patients in the placebo arm crossed over, but despite the high crossover rate, there was still a trend for median OS improvement.
In a respecified analysis, the adjusted median OS still demonstrated significant improvement with ivosidenib, says Zhu. In addition, when looking at the safety of this therapy in patients with cholangiocarcinoma, the agent had a very favorable safety profile. According to Zhu, these findings are encouraging.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
